This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Newron Pharmaceuticals SpA
Drug Names(s): 7-beta-hydroxyepiandrosterone, 7-beta-OH-EPIA
Description: HF0220 is a naturally occurring steroid which affects levels of certain prostaglandins, though its precise mechanism of action is not known. It increases levels of the anti-inflammatory prostaglandin J2 (15d-PGJ2) and reduces levels of levels of the pro-inflammatory prostaglandin E2 (PGE2). In preclinical studies, it reduces the level of amyloid beta in a model of Alzheimer's disease, and is protective in models of stroke and collagen induced arthritis.
HF0220 does not demonstrate specific binding to classical steroid hormone and glucocorticoid receptors.
Deal Structure: HF0220 was originally developed by Hunter-Fleming Ltd.
Newron and Hunter-Fleming
In February 2008, Newron Pharmaceuticals announced the acquisition of Hunter-Fleming. The agreement provides for the acquisition of 100% of the issued share capital of Hunter-Fleming. Newron will make an upfront payment of 8m, minus net debt, for the fully diluted share capital of Hunter-Fleming, in newly issued Newron shares. In addition, success-based milestones related to the Hunter-Fleming programs will be made up to a maximum of 17m, in newly issued Newron shares.
Newron and Biotie
In September 2011, Biotie Therapies and Newron Pharmaceuticals announced that they signed an agreement for Biotie to acquire Newron. In October 2011, Biotie notified Newron of its decision to exercise its right to terminate the Merger Plan and combination agreement, without further obligations from Biotie.
Additional information available to subscribers only: